SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
about
p21-Activated kinase inhibitors: a patent reviewSynthesis of New Functionalized Indoles Based on Ethyl Indol-2-carboxylate.Sunitinib combined with angiotensin-2 type-1 receptor antagonists induces more necrosis: a murine xenograft model of renal cell carcinoma.Targeting of the breast cancer microenvironment with a potent and linkable oxindole based antiangiogenic small molecule.Domain-based biosensor assay to screen for epidermal growth factor receptor modulators in live cellsStructure, development, preclinical and clinical efficacy of tivozanib (KRN-951, AV-951).Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.Signaling from the human melanocortin 1 receptor to ERK1 and ERK2 mitogen-activated protein kinases involves transactivation of cKIT.Vascular endothelial growth factor receptor-2 inhibitor cediranib causes regression of endometriotic lesions in a rat modelGold-containing indoles as anticancer agents that potentiate the cytotoxic effects of ionizing radiation.The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops.Antioxidant & anticancer activities of isatin (1H-indole-2,3-dione), isolated from the flowers of Couroupita guianensis Aubl.VEGF/VEGFR signalling as a target for inhibiting angiogenesis.Emerging drugs for the treatment of metastatic renal cancer.Mechanisms of resistance to FLT3 inhibitors.Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates Apatinib treatment efficacy in gastric cancer.Bench to bedside targeting of FLT3 in acute leukemia.Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?Cognitive dysfunction and cancer: which consequences in terms of disease management?FMS-like tyrosine kinase 3 inhibitors: a patent review.FMS Kinase Inhibitors: Current Status and Future Prospects.Axitinib for the treatment of advanced non-small-cell lung cancer.Current status and future prospects for anti-angiogenic therapies in cancer.Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects.Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development.Mechanisms of apoptosis in irradiated and sunitinib-treated follicular thyroid cancer cells.Successful treatment of advanced pancreatic liposarcoma with apatinib: A case report and literature review.Management of metastatic renal cell carcinoma in patients with poor prognosis.Osteonecrosis of the Jaws in Patient Received Bisphosphonates and Sunitinib Separately: A Case ReportThe use of sunitinib in renal cell carcinoma: where are we now?Association of polymorphisms in FLT3, EGFR, ALOX5, and NEIL3 with glioblastoma in the Han Chinese population.A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis.
P2860
Q28261519-620376D7-160F-46F3-AB88-FBE11FF0C57EQ31058551-2D5E6324-10D8-40AB-878B-A011CF4A706DQ33745382-F556EFCD-63F9-450C-8A09-211B3ED0BE5DQ33913901-F2B439CE-572C-4EA2-A2E3-FFFEA2CD8610Q34141984-6633187F-DBDF-46F6-A5A5-FF734EAEBE7CQ34517849-40E44D68-E22D-46A2-A57E-F8F0F3076730Q34591403-5DC81B13-592C-42DD-914E-8DB00AA69E5AQ34943036-B22C6FFB-F8DB-46DA-8BB7-8EA733C2B3F7Q35406146-A9285169-EAAF-4DFD-B7BC-D6C2AC1E7D5FQ35889822-BA7CACFB-D0AF-4034-8CA7-B43CEA00C8F9Q36172732-9C3F6D9D-D5A9-41AA-9305-0C24639F2ABEQ36613191-ECB0597D-06C1-47D8-BEFC-3B910AB26DE3Q36677407-7472A8BC-BA47-471D-B50D-C30FD7A9B2BAQ36989925-E382406A-F795-4A7D-89EE-B712E058B441Q37375423-E096A9EA-6F7B-4598-8669-18FCB60FA6DDQ37707033-3C17DC19-31C2-4B3C-85ED-494B99B8B593Q37724957-326298AC-AA2A-417E-8229-C122E08E60FCQ37799821-1E257D7C-EC3E-4A41-B42B-5B5739A804C9Q37831271-CC7F088F-753A-403C-A7A4-AEE38CB16425Q37842585-975BDBFD-7247-4439-9A77-BC635F69E500Q37995562-7431B983-2EC8-42A3-82A3-08CCB7DB3EC2Q38085684-7EF96B1F-1AC7-493C-B92C-07017FBCD11DQ38088366-663BFBC6-79E7-441F-A40F-F37EC6FE921FQ38093654-76FE82F2-D151-4D25-BF93-5860EC1EFA1AQ38262816-267C40D0-F0AD-40F6-865D-46D25732FADAQ39064895-EFD1EB97-53C9-4923-8034-E502C0A1224EQ39415516-CC990FB3-460D-40F9-9BDB-7BA305ED8259Q41242405-D979EC34-C08F-44F2-BD1F-9B69DF24CFD0Q42269851-B3E3F964-9FDE-4A77-9606-72A782E2F2AFQ48634468-6B285D4F-C712-4081-92C7-AC21B6CE8B07Q49072873-1E954C10-BF58-4225-A2D2-A97DA8FD5DFCQ51168424-6A8FE0C3-82DC-4708-A48F-D72D369FE7BF
P2860
SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
SU14813: a novel multiple rece ...... ogenic and antitumor activity.
@ast
SU14813: a novel multiple rece ...... ogenic and antitumor activity.
@en
type
label
SU14813: a novel multiple rece ...... ogenic and antitumor activity.
@ast
SU14813: a novel multiple rece ...... ogenic and antitumor activity.
@en
prefLabel
SU14813: a novel multiple rece ...... ogenic and antitumor activity.
@ast
SU14813: a novel multiple rece ...... ogenic and antitumor activity.
@en
P2093
P1476
SU14813: a novel multiple rece ...... ogenic and antitumor activity.
@en
P2093
A Douglas Laird
Anne-Marie O'farrell
Cheng Y Yang
Chris Liang
Dana Hu-Lowe
Dirk B Mendel
Huiping Guan
Jeffrey Chen
Joshua O Haznedar
Julie M Cherrington
P304
P356
10.1158/1535-7163.MCT-05-0333
P577
2006-07-01T00:00:00Z